Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.44 |
| ▸ | HTR6 | P50406 | 8/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14701094 | 0.88 | AR (0.40) | ARHTR6PTGS1PTGS2ALDH1A1 | |
| SCHEMBL14702106 | 0.84 | AR (0.41) | ARHTR6PTGS1PTGS2ALDH1A1 | |
| SCHEMBL2358789 | 0.79 | HTR6 (0.35) | HTR6PTGS1PTGS2ALDH1A1LMNA | |
| SCHEMBL14701016 | 0.78 | AR (0.44) | ARHTR6PTGS1PTGS2ALDH1A1 | |
| SCHEMBL18804022 | 0.76 | AR (0.45) | ARHTR6PTGS1PTGS2ALDH1A1 | |
| SCHEMBL14688617 | 0.75 | HTR6 (0.36) | HTR6PTGS1PTGS2ALDH1A1LMNA | |
| SCHEMBL2360380 | 0.75 | HTR6 (0.35) | ARHTR6PTGS1PTGS2ALDH1A1 | |
| SCHEMBL2360445 | 0.72 | HTR6 (0.42) | HTR6PTGS1PTGS2ALDH1A1LMNA | |
| SCHEMBL2319772 | 0.71 | KDM4E (0.49) | HTR6PTGS1PTGS2ALDH1A1LMNA | |
| SCHEMBL2359831 | 0.70 | HTR6 (0.38) | ARHTR6PTGS1PTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987319-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987319-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130041007-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. | 2013-02-14 | — | — | US | disclosed |
| US-20130041007-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130041007-A1 | Selective Androgen Receptor Modulators | AR, SHBG, GPR119 | AR 1/4885HTR6 683/4885PTGS1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.